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Abstract 
Background 
Synapses are fundamental components of brain circuits and are disrupted in over 100 
neurological and psychiatric diseases. The synapse proteome is physically organized into 
multiprotein complexes and polygenic mutations converge on postsynaptic complexes in 
schizophrenia, autism and intellectual disability. Directly characterising human synapses and 
their multiprotein complexes from post-mortem tissue is essential to understanding disease 
mechanisms. However, multiprotein complexes have not been directly isolated from human 
synapses and the feasibility of their isolation from post-mortem tissue is unknown. 
Results 
Here we establish a screening assay and criteria to identify post-mortem brain samples 
containing well-preserved synapse proteomes, revealing that neocortex samples are best 
preserved. We also develop a rapid method for the isolation of synapse proteomes from 
human brain, allowing large numbers of post-mortem samples to be processed in a short time 
frame. We perform the first purification and proteomic mass spectrometry analysis of 
MAGUK Associated Signalling Complexes (MASC) from neurosurgical and post-mortem 
tissue and find genetic evidence for their involvement in over seventy human brain diseases. 
Conclusions 
We have demonstrated that synaptic proteome integrity can be rapidly assessed from human 
post-mortem brain samples prior to its analysis with sophisticated proteomic methods. We 
have also shown that proteomics of synapse multiprotein complexes from well preserved 
post-mortem tissue is possible, obtaining structures highly similar to those isolated from 
biopsy tissue. Finally we have shown that MASC from human synapses are involved with 
over seventy brain disorders. These findings should have wide application in understanding 
the synaptic basis of psychiatric and other mental disorders. 
Keywords 
Synapse, Proteomics, Mass spectrometry, Supercomplex, Post-mortem brain, MAGUK, 
Psychiatric disorder 
Background 
Synapse proteomics involves the comprehensive analysis of individual synapse proteins and 
their organization and assembly into multiprotein complexes [1]. Proteomic mass 
spectrometry analysis of mammalian synapses demonstrated that synapse proteomes are 
highly complex with over 1000 proteins in humans [2,3]. This knowledge, combined with 
human genetic studies, enabled the systematic identification and classification of human 
diseases involving synapse proteins, which are now referred to as Synaptopathies [4]. Several 
reports [5-9] show it is feasible to profile individual proteins in the human postsynaptic 
density (PSD) proteome from post-mortem tissue and three studies in Alzheimer’s Disease 
[7,8] and alcohol addiction [9] show the potential for direct molecular studies of 
synaptopathy. 
To date there are no proteomic studies of synaptic multiprotein complexes from either post-
mortem (PM) or neurosurgical biopsy (NSB) material. In mice virtually all synapse proteins 
are assembled into supramolecular complexes, some of which are in turn assembled into 
supercomplexes [10,11]. These can be isolated using a variety of affinity purification 
methods including peptides, chemical ligands, antibodies and genetically encoded affinity 
tags [4,12,13]. The prototype postsynaptic supercomplexes are known as MASC (MAGUK 
Associated Signalling Complexes) and they are organized around scaffolding proteins 
encoded by the DLG/MAGUK gene family. Humans and mice have 4 DLG paralogues: 
DLG1/SAP97, DLG2/PSD93, DLG3/SAP102 and DLG4/PSD95. MASCs were originally 
characterized from mouse brain and are ~2MDa in size, containing, among other proteins, 
glutamate receptors, signalling proteins and potassium channels [12,14]. The importance of 
MASCs for cognition is emphasized by human genetic studies of mental disorders including 
schizophrenia, autism, intellectual disability and other diseases, which show mutations in 
MASC components [15-18]; similarly, mutations of MASC genes in mice also result in 
cognitive impairments [4,19-21]. 
To better understand synaptic biochemical variations in health and disease, the ability to 
isolate and characterize MASC from PM human brain is critical. Unfortunately, the greatest 
obstacle to human synapse proteomics is the protein degradation that occurs due to ante- and 
post-mortem conditions. Although brain banks report indices for assessing sample quality 
such as PM time interval, tissue pH and an RNA integrity index (RIN), their relevance for 
proteome integrity is unknown. Here we have surveyed the variability and suitability of PM 
tissue with the purpose of isolating and characterizing postsynaptic protein complexes using 
proteomics. We report that standard brain quality indicators from tissue banks poorly predict 
the integrity of the postsynaptic proteome and we have developed a new index that is a robust 
correlate of synapse proteome integrity allowing proteomic analysis of MASC from PM 
samples. These studies and their data resources reveal the importance of human MASC in a 
large number of human diseases. The new approaches will also facilitate isolation of other 
synapse multiprotein complexes and their direct study in diseased tissue. All the data 
generated in this study is freely available in the G2Cdb database 
(http://www.genes2cognition.org/publications/human-masc). 
Results and discussion 
Rapid isolation of postsynaptic fractions from small PM samples 
Our initial objectives were to i) enhance sample preparation speed to improve preservation of 
protein complexes and allow greater numbers of samples to be analysed, and ii) increase 
protein yield enabling studies on small amounts of tissue. We reduced the duration of the 
isolation of postsynapse-enriched fractions from 6–8 hours [22] to 2 hours by removing the 
density gradient fractionation step and maintaining the well-known non-ionic detergent 
insolubility of the PSD of excitatory synapses (Figure 1a, see methods). The high protein 
yield (2.8 ± 0.13 μg SEM, n = 35 protein in P2 fraction / mg of tissue) of this protocol 
enabled a 10-fold reduction in the amount of starting material permitting routine isolation of 
synaptic-enriched structures from as little as 100 mg of human brain tissue. Enrichment of 
synapse proteins in the P2 fraction was confirmed (Figure 1b-c). 
Figure 1 Method for rapid isolation of synaptic-enriched fractions from PM human 
cortex. GluN2B degradation and correlation with number of intact PSD proteins. A. 
Schematic representation of the subcellular fractionation method used to obtain postsynaptic 
protein enriched fractions (P2). Procedure time is indicated. H and S, homogenized cortex; 
P1, nucleus/cell debris; S1, cytosolic fraction; P2, triton insoluble fraction; S2, triton soluble 
fraction. B. Immunoblot showing protein enrichment or depletion between sample S and P2 
from isolation protocol described in A. Postsynaptic markers: PSD95/DLG4, GluN2B and 
SAP102/DLG3. Pre-synaptic-markers: SYP and VGluT-1. A marker of mitochondria is also 
included: COXIV-1. C. Mean fold enrichment of proteins in final P2 fraction compared to 
starting S fraction analysed by immunoblotting (n =5). Postsynaptic proteins were enriched in 
P2, while presynaptic and mitochondrial markers were depleted (S/P2 < 1). D. GluN2B 
immunoblot from control NSB and 28 PM samples (Additional file 1). PM samples show 
three main bands, band 1 corresponding with the full-length protein. The ratio of band 1 over 
band 2 intensities provides HUSPIR ratio. The antibody used was designed against the C-
terminal region of GluN2B (BD Bioscience ref. 610416). E. For each PM sample the 
HUSPIR ratio is plotted against the number of intact PSD proteins. Significant positive 
Spearman’s coefficient of correlation (r) and p-value (p) are indicated. F. HUSPIR ratio for 
the set of 28 unselected samples and the set of 9 samples selected. Median and interquartile 
range shown. G. Comparison between percentage of PSD components observed in the set of 
28 unselected samples and the prospective set of 9 selected samples. Median and interquartile 
range shown. 
Next, we applied this protocol to 28 randomly selected PM brains from the MRC Edinburgh 
Brain Bank (Additional file 1) and assessed the degradation of 20 important postsynaptic 
proteins using immunoblotting (Additional file 2: Figure S1). Comparison with control NSB 
tissue (Additional file 2: Figure S1) permitted counting and scoring of the integrity of each 
protein in each PM sample. The correlation coefficient for the number of intact proteins in 
each sample compared with Brain Bank quality indicators including RNA integrity, time 
since death and other measures (Table 1) was calculated. We failed to find statistical 
significance in any of these correlations, indicating these measures do not reliably predict 
synapse proteome integrity; which triggered us to develop a new method to evaluate synaptic 
proteome integrity that could be readily applied to PM samples. 
Table 1 Correlation between brain bank tissue quality parameters and number of 
detected postsynaptic density proteins 
Parameter Spearman r p value (two-tailed) 
PM Interval 0.01079 0.9566 (n.s.) 
(n = 28) 
pH −0.075 0.1193 (n.s.) 
(n = 25) 
RNA Integrity Number (RIN) 0.1193 0.6163 (n.s.) 
(n = 20) 
Intensity of GluN2B Band 1/Band 2 0.5905 0.0009 (***) 
(n = 28) 
Intensity of GluN2B Band 1/Band 3 −0.01091 0.956 (n.s.) 
(n = 28) 
Intensity of GluN2B Band 1/Band 2 + Band 3 0.4831 0.0092 (**) 
(n = 28) 
Number in brackets indicates the number of tissue samples (out of 28) with a value for that particular parameter; n.s. not 
significant; *** p < 0.001 and ** p < 0.01. 
A simple screening method to measure PM synapse proteome integrity 
Inspection of these 20 immunoblots (Additional file 2: Figure S1) revealed that PM samples 
in GluN2B (2B subunit of the N-methyl-D-aspartate glutamate receptor) presented two low-
molecular weight bands (see bands 2 and 3 on Figure 1d) that corresponded with GluN2B 
proteolysis products due to PM conditions according to what has been described previously 
[23]. These degradation products, which are absent from biopsy samples (NSB, Figure 1d), 
are already apparent 2 hours after death [23]. Different PM samples showed different 
intensities for these three bands; for instance, some samples lacked all three bands (sample 
18/07) indicating complete degradation of the receptor and some lacked only the uppermost 
Band 1 (samples 19/06 or 19/08) indicating partial degradation. To estimate the extent of 
degradation of each sample, the ratio of Band 1/Band 2 intensity was measured for all 28 
samples (median ratio: 0.83). We next correlated these values with the counts of present 
immunoblotted PSD proteins (Additional file 2: Figure S1) and in contrast to what was 
observed with brain bank indicators, we found significant positive correlation (Spearman’s 
rho =0.59, P <0.001, Figure 1e). These results suggest this ratio can be used to estimate 
synaptic proteome preservation in PM brain samples and hereafter we refer to this ratio as 
HUSPIR (HUman Synapse Proteome Integrity Ratio). 
To validate the usefulness of HUSPIR we prospectively screened another group of nine PM 
samples (Selected PM Group) that were presumed to be of high quality since they were 
obtained from individuals who died suddenly, before the age of 60, had a short agonal state 
and PM interval, and showed no detectable neuropathological abnormalities. The median 
HUSPIR value for this group (2.43, Figure 1f) was significantly higher (p =0.001; Mann 
Whitney Test) than the median HUSPIR for the initial set (Unselected PM Group, Figure 1f). 
As predicted by HUSPIR the selected group presented all PSD components analysed by 
immunoblotting (Figure 1g and Additional file 2: Figure S2). These results confirm that the 
simple and rapid measurement of HUSPIR, based on GluN2B band ratios, reliably predicts 
synapse proteome integrity. Based on these results, we propose using PM samples with a 
HUSPIR >1 for biochemical evaluation. 
Synaptic proteome integrity varies between cortical and other brain regions 
We were also interested in evaluating if postsynaptic proteome integrity was homogenous 
between different areas of the same brain. To address this issue we isolated postsynaptic 
densities (PSD) from 26 different brain regions in 4 different post-mortem brains from the 
‘sudden-death brain bank collection’ (Edinburgh MRC-Brain Bank). These regions included 
13 cortical areas, 5 limbic structures and 8 sub-cortical regions (Figure 2). Each isolated PSD 
fraction was subjected to GluN2B immunoblot (Figure 2a,b) to determine its corresponding 
HUSPIR value. 
Figure 2 Comparative GluN2B degradation between brain areas. A. Representative 
immunoblot of GluN2B for 13 different cortical regions from brain SD025/13 (Additional 
file 1). These cortical regions included the Broadmann Areas (BA) 4, 11/12, 17, 19, 20/21, 
37, 38, 39, 41/42 and 44/45 (Broca’s area), as well as three frontal cortex samples: frontal 
convexity (FC), anterior frontal convexity (Ant FC) and anterior frontal parasagital (Ant 
FPS). GluN2B degradation bands are indicated. B. Representative immunoblot of GluN2B 
for 5 limbic areas: Broadmann areas (BA) 23 and 24, anterior and posterior Hipocampus 
(HC) and amygdala (Amyg); and 8 sub-cortical regions: Pons, Midbrain (MB), Caudate 
nucleus (Caud nuc), Thalamus (Thal), Medulla (Med), Vermis, Basal ganglia mammillary 
body (BG mam) and Cerebellum (CB). GluN2B degradation bands are indicated. C. Plot 
summarizing HUSPIR values for 26 brain areas (13 cortical, 5 limbic and 8 sub-cortical) 
analysed by immunoblot for GluN2B degradation in 4 different brains (SD025/13, SD042/13, 
SD032/13 and SD023/13). HUSPIR values above one are indicated in green and below in 
red. Grey indicates no measure could be taken. 
As summarized in Figure 2c HUSPIR values varied importantly between cortical and other 
brain regions. While most HUSPIR values for cortical regions were above 1, suggesting a 
good preservation of its postsynaptic proteome, other brain regions showed a HUSPIR <1 in 
more than half of the samples analysed (34/52; Figure 2c). The fact that limbic areas 
anatomically close to the cortex (cingulate gyrus: BA23 and BA24) show high HUSPIR 
values in the 4 brains analysed gives further evidence for a better preservation of the synaptic 
proteome in more anterior brain regions. Finally, this data also indicates that when working 
with non-cortical brain areas HUSPIR should be measured for each brain sample included in 
the study. The HUSPIR value of one cortical region has a good predictive value for other 
cortical regions of the same brain, as shown in Figure 2c. 
Isolation and proteomics of human MAGUK associated signalling complexes 
In the next phase of our study we have combined the new methods for screening samples 
with well preserved synaptic proteomes with affinity methods to isolate MAGUK Associated 
Signalling Complexes (MASC). This affinity method relies on a 6 amino acid immobilized 
peptide (pep6, SIESDV) that binds to PDZ domains of MAGUK proteins and a control 
peptide (pep6δV, SSIESD) that cannot bind to these domains [24]. We used this protocol, 
which involves the use of stringent biochemical methods, to ask if it was possible to isolate 
MASC from 3 PM human frontal cortex samples with HUSPIR >1 (Additional file 1). As a 
positive control we used the same protocol on 3 NSB samples and as a further positive 
control, we also isolated MASCs from mouse cortex. As shown in the coomassie stained 
SDS-PAGE gel (Figure 3a), all samples showed strong recovery of multiple proteins with 
pep6, and as expected, a low background with pep6δV purifications. Immunoblotting of these 
samples with antibodies to three MAGUK proteins (DLG2/PSD93, DLG3/SAP102, 
DLG4/PSD-95) showed robust signals in pep6 samples and no signal in negative controls 
(Figure 3b). These results show that it is possible to affinity isolate MASCs from NSB as 
well as PM human brain and we hereafter refer to these isolates as hMASC. 
Figure 3 Affinity purification of the MAGUK Associated Signalling Complexes (MASC) 
from brain cortex and observed MASC composition in NSB or PM frontal cortex. A. 
Coomassie stained SDS-PAGE electrophoresis of MASC complexes isolated by affinity 
purification from mouse cortex, human NSB and PM frontal cortex. Human sample details in 
Additional file 1. MW: Molecular Weight markers; pep6, eluate from affinity purification 
using pep6 peptide; pep6δV, eluate from affinity purification using control peptide. B. 
Immunoblots of three members of the DLG4/PSD-95 family (DLG4/PSD-95, DLG3/SAP102 
and DLG2/PSD-93) for 6 human MASC purifications (pep6), and corresponding controls 
(pep6δV); three from NSB and three from PM frontal cortex. C. Panther Protein Classes in 
the postsynaptic proteome (in green), the NSB MASC (in red) or the PM MASC (in blue) 
that are significantly enriched as compared with the human genome. Bar height corresponds 
with percentage of all proteins found in that Protein Class. (See Additional file 2 for methods 
and detailed bioinformatics functional analysis). 
We next identified all proteins in hMASC samples using mass spectrometry and used 
bioinformatics to compare PM and NSB components (Additional file 3). See Additional file 2 
for detailed bioinformatics functional analysis of hMASC. In total we found 239 and 227 
proteins in NSB and PM hMASC respectively. A very large proportion (>75%) of NSB 
hMASC proteins were found in PM hMASC complexes, demonstrating for the first time that 
it is possible to isolate bona fide synaptic multiprotein complexes from PM samples if these 
have a HUSPIR value >1. These results also indicate the applicability and robustness of the 
affinity isolation methods developed here to analyse human PM brain tissue. Comparison of 
the functional types of proteins in PM and NSB hMASC showed a high similarity (Figure 3c 
and Additional file 4). 
Despite the high degree of similarity between NSB and PM hMASCs we reasoned that some 
protein types are likely more vulnerable to PM conditions than others. If this is the case it is 
important to identify them, as these will be underrepresented in PM hMASCs. We analysed 
several protein features, including protein length, isoelectric point, presence of 
transmembrane regions, and protein turn-over [25], in proteins isolated from both tissue 
sources. Overall, proteins found in NSB and PM hMASCs showed only minor differences 
among these variables. Only protein length was slightly biased, with proteins found in two or 
three triplicate samples somewhat longer in NSB hMASC compared to PM hMASC (median 
length 558, compared to 428 residues, respectively; p =0.033, Mann Whitney Test). Next we 
compiled a list of the specific proteins with differential expression and noted this included 
proteins involved with activity-dependent reorganization of the synaptic proteome, including 
calcium-calmodulin dependent kinases (CAMK2A, B and G), scaffold proteins of the 
DLGAP family, G-proteins and elements of the tubulin cytoskeleton (Additional file 2: 
Figure S3). In contrast to these unstable components, the more stable groups included the 
MAGUK scaffold proteins, their associated NMDA receptors, signalling and cytoskeletal 
proteins, among others (Additional file 2: Figure S4). 
Human MASC proteins in disease 
To understand the relevance of hMASC to human disease we searched online genetics 
databases and the published human genetics literature for evidence of hMASC genes 
involved in brain disorders (see methods). Our approach involved: i) identification of relevant 
genes and relevant diseases, ii) allocation of diseases into specific categories according to the 
International classification of Disease System (ICD-10), iii) statistical analysis of the 
representation of disease categories, and iv) comparison of hMASC with hPSD to examine 
the relative importance of hMASC, as compared with the whole postsynaptic density. 
According to OMIM database of inherited diseases [26] 66 hMASC genes are involved with 
93 genetic diseases. Fifty-one of these are nervous system diseases with 47 specific to the 
CNS. Literature text-mining and curation identified CNS diseases for which hMASC genes 
were positively associated, bringing the total number of CNS diseases related to the hMASC 
to 76. Classification with ICD-10 of these CNS diseases showed they include rare monogenic 
disorders as well as complex, more common psychiatric and neurologic disorders, including 
Schizophrenia and Autism spectrum disorder (Additional file 5). We next asked whether 
particular disease categories were over- or under-represented in hMASC compared to the 
postsynaptic proteome (hPSD, see Bayés et al. [2]). Looking into inherited diseases, we 
found a two-fold greater proportion of hMASC genes (both NSB and PM) involved with 
CNS compared with hPSD genes (Figure 4a). As shown in Figure 4b, the ‘Disorders of the 
Nervous System’ and ‘Mental and Behavioural Disorders’ ICD-10 categories were over-
represented relative to the hPSD, whereas the hPSD was more enriched in Endocrine, 
Nutritional and Metabolic Diseases than hMASC (Figure 4b). As hMASC was most enriched 
for Mental & behavioural Disorders, we examined Intellectual Disability disorders in more 
detail. We created a database of genes causing any form of ID (ID) and non-syndromic ID 
(NSID) (Additional file 6) and found a significant over-representation of hMASC and hPSD 
genes in both these types of ID, with NSID highest (Figure 4c,d). 
Figure 4 Involvement of MASC proteins in genetic diseases. A. Percentage of genes 
expressed in human NSB MASC, PM MASC and PSD causing central nervous system 
diseases included in OMIM. B. Proportion of CNS diseases caused by genes found in human 
NSB MASC (red), PM MASC (blue) and PSD (green). ICD-10 groups (Chapters) indicated 
on x-axis: Congenital Malformations refers to ICD-10 Chapter XVII, Nervous System 
Diseases refers to ICD-10 Chapter VI, Endocrine and metabolic refers to ICD-10 Chapter IV 
and Mental and Behavioural refer to ICD-10 Chapter V. Means compared by Student’s t-test. 
C. Genes expressed at the postsynapse causing any form of genetic Intellectual Disability 
(ID). For each postsynaptic protein complex pale columns indicate number of genes causing 
ID and dark columns the expected number to be found by chance. Binomial statistics are used 
to compute significance of the difference between observed and expected (Binomial 
Statistics, ***, p <1E-05; **, p <1E-03; *, p <0,05). D. Genes expressed at the postsynapse 
causing any form of genetic non-syndromic Intellectual Disability (NSID). For each 
postsynaptic protein complex pale columns indicate number of genes causing ID and dark 
columns the expected number to be found by chance. Binomial statistics are used to compute 
significance of the difference between observed and expected (Binomial Statistics, ***, p 
<1E-05; **, p <1E-03; *, p <0,05). 
Conclusions 
We developed a simple method for determining if the synapse proteome integrity of a PM 
sample is sufficient for proteomics and rapid biochemical methods for the isolation of 
synapse-enriched fractions from small amounts of human PM tissue. In around two hours, 
synaptic proteomes can be obtained from as little as 100 mg of starting tissue, allowing for 
the parallel analysis of large numbers of samples. We have also shown that the HUman 
Synaptic Proteome Integrity Ratio (HUSPIR), an indicator of postsynaptic proteome 
integrity, denotes that the synaptic proteome is better conserved in cortical than other brain 
regions. Using these approaches we have also performed the first isolation and proteomic 
characterization of human MAGUK Associated Signalling Complexes and identified 76 CNS 
diseases involving MASC proteins, of which 47 are inherited disorders. The centrality of 
hMASC to human synapse function and human synaptic diseases is evidenced by the 
comparison of the hMASC and hPSD proteomes and their relevant genetic diseases. 
Of the many diseases impacting on the synapse, hMASC is particularly important for those 
with cognitive components including ID, schizophrenia and autism. Recent whole exome 
analyses of schizophrenia show convergence of multiple mutations onto hMASC [15,16] and 
population studies show IQ is associated with genetic variation in hMASC genes [27]. 
Comparison of human and mouse synapse proteome orthologues shows a high degree of 
conservation in MASC and PSD proteins consistent with conserved functions [2]. Moreover, 
comparative cognitive testing with computerized touchscreen tests show MAGUK proteins in 
both species have conserved regulation of cognitive components [21]. 
Future studies on human synapse proteomes could use the Human Synapse Proteome 
Integrity Ratio (HUSPIR) to identify PM samples suitable for sophisticated proteomics from 
the thousands of stored brain bank samples. We were surprised to find that ~30% of cortical 
samples in the Edinburgh Brain Bank met the criteria of a HUSPIR >1, which suggests that 
large numbers of samples are suitable for analysis. Quantitative analysis of whole synapses or 
their subcomponents including hMASC can now be applied on a large scale to characterize 
human synaptopathies directly in human tissue. In addition to the use of HUSPIR, the 
identification of stable proteins indicates that these proteins and their relevant diseases will be 
better suited for study than those involving labile proteins. Synapse proteomics has identified 
a striking number of diseases that impact on the synapse and further development of methods 
for the study of human synaptopathy may have a major impact on neuropathology and 
diagnosis in the future. All the data generated in this study is freely available in the G2Cdb 
database (http://www.genes2cognition.org/publications/human-masc). 
Methods 
Human neocortex samples 
NSB samples were obtained from frontal cortex by Prof. Ian Whittle (Edinburgh University) 
in a study approved by the Lothian Region Ethics Committee (number /2004/4/16). Informed 
consent was obtained from all donors. All PM tissue was obtained from the Medical Research 
Council Edinburgh Brain Bank (Additional file 1). The three PM samples used to purify 
MASC were from the frontal cortex (Additional file 1). 
Rapid isolation of postsynaptic fractions from PM tissue 
To facilitate characterization of the human postsynaptic proteome we developed biochemical 
methods based on those used in rodents [28,29]. Approximately 300 mg of grey matter was 
routinely used for isolation of synaptic fractions; nevertheless, the protocol can be scaled 
down to 100 mg of starting material. Prior to tissue processing, white matter was removed 
from frozen cortex blocks. Grey matter was homogenized with a glass-teflon dounce (tissue 
weight/buffer volume ratio of 100 mg:1 ml) in a buffer containing 0.32 M sucrose, 10 mM 
HEPES pH 7.4, 2 mM EDTA, 5 mM sodium O-vanadate, 30 mM NaF and protease inhibitors 
cocktail (Roche). Homogenized tissue was centrifuged at 800xg for 15 min at 4°C; 
supernatant removed and centrifuged at 10,000xg for 15 min. The pellet was resuspended in 
Triton buffer (50 mM HEPES pH 7.4, 2 mM EDTA, 5 mM EGTA, 5 mM sodium-O-
vanadate, 30 mM NaF, 1% Triton X-100 and protease inhibitors cocktail (Roche)) with half 
the volume used for homogenization. Sample was then centrifuged at 30,000xg for 30 min at 
4°C and the final pellet was resuspended in 200 μl of SDS buffer (50 mM Tris pH 7.4, 1% 
SDS) and used for immunoblotting. 
Isolation of postsynaptic densities from human post-mortem brain samples 
Postsynaptic densities were isolated using standard differential ultracentrifugation methods. 
Briefly, dissected tissues was homogenized in buffer A (0.32 M sucrose, 2 mM HEPES, pH 
7.4, 1 tablet of complete EDTA-free protease inhibitor (Roche), phosphatase inhibitor 
cocktail set II (Calbiochem) using a Dounce homogenizer. The resulting homogenate was 
centrifuged at 1000 xg for 10 min at 4°C. The pellet was rehomogenized in the same buffer 
and centrifuged at 1000 xg for 10 min at 4°C. The two supernatants were pooled and 
centrifuged at 18600 xg for 15 min at 4°C. The next pellet was resuspended in buffer B (1.5 
M sucrose and 50 mM Tris–HCl, pH 7.4 containing the same protease and phosphatase 
inhibitors as in buffer A). A discontinuous sucrose gradient was built by layering equal 
volumes of the resuspended pellet (bottom), 0.85 M and 0.3 M sucrose in 50 mM Tris–HCl, 
pH 7.4. This gradient was centrifuged at 60000 xg for 42 min using a MLA-55 rotor 
(Beckman-Coulter). The interface between 1.5 M and 0.85 M sucrose, corresponding to the 
synaptosomal fraction, was collected, diluted in 2 volumes of 50 mM Tris–HCl, pH 7.4 and 
centrifuged at 48000 xg for 30 min at 4°C. The resulting pellet was resuspended in 1.5% 
Triton X-100, 25 mM Tris–HCl, pH 7.4, incubated on ice for 30 min, layered on top of a 0.85 
M sucrose solution in 50 mM Tris–HCl, pH 7.4 and centrifuged at 104000 xg for 30 min at 
4°C. The resulting postsynaptic density pellet was resuspended in 50 mM Tris–HCl, pH 7.4 
and 10% glycerol and mixed with SDS-PAGE electrophoresis loading buffer. 
Isolation of human MAGUK Associated Signalling Complexes (MASC) 
MASCs were isolated from human NSB or PM frontal cortex using an improved version of 
an affinity purification protocol developed with mouse brain samples [12]. Briefly, this 
method used a peptide corresponding to the six carboxyl terminal residues of GluN2A and 
GluN2B, which bind PDZ domains of Membrane Associated Guanylate Kinase (MAGUK) 
proteins (DLG4/PSD95, DLG2/PSD93, DLG3/SAP102 & DLG1/SAP97) [30,31]. A negative 
control for the affinity purification uses a peptide lacking the C-terminal valine residue [24]. 
Brain tissue was homogenized (tissue weight:volume ratio of 100 mg:1.85 ml) with DOC 
Buffer (Tris 50 mM pH 9.0, 1% sodium deoxycholate, 50 mM NaF, 20 μM ZnCl2, 1 mM 
Sodium ortho-vanadate and protease inhibitors cocktail (Roche)). The homogenized sample 
was centrifuged at 50,000 g for 30 min and pellet discarded. For affinity purification, 
peptides were first bound to Affi-Gel 10 resin (Bio-Rad) at a 5 mg/ml concentration 
following manufacturers indications. Brain homogenate and peptide-bound resin were mixed 
at 1:100 (v/v) ratio and incubated over-night at 4°C with agitation. Prior to elution, resin was 
washed five times with 5 column volumes of DOC Buffer. Elution was performed with DOC 
Buffer containing free peptide at 5 mg/ml. Eluted sample was reduced by adding fresh DTT 
(SIGMA) to a final concentration of 1 mM and heating at 70°C for 10 minutes. Reduced 
sample was carboxymethylated by adding fresh iodoacetamide (SIGMA) to final 
concentration of 2 mM and incubated in the dark at room temperature for 30 minutes. 
Sample preparation for QUANTITATIVE MS 
In gel digestion was performed as reported previously [2]. Extracted peptides were isotope 
labelled using a triplex dimethylation strategy [32,33] and labelled peptides pooled for LC-
MS/MS analysis. This was done as follows: Light labelling: Neg. Control (50% from biopsy 
and 50% from PM Pep6δV), Medium labelling: Biopsy Pep6, Heavy labelling: PM Pep6. 
Pooled peptide samples from each of the 12 gel bands were analysed separately by nanoLC-
MS/MS on a LTQ Orbitrap Velos (Thermo Fisher) hybrid mass spectrometer equipped with a 
nanospray source, coupled with an Ultimate 3000 Nano/Capillary LC System (Dionex). The 
system was controlled by Xcalibur 2.1 (Thermo Fisher) and DCMSLink 2.08 (Dionex). 
Peptides were desalted on-line using a micro-Precolumn cartridge (C18 Pepmap 100, LC 
Packings) and then separated using a 60 min RP gradient (4-32% acetonitrile/0.1% formic 
acid) on a BEH C18 analytical column (1.7μm, 75 μm id × 10 cm,) (Waters). The LTQ-
Orbitrap Velos was operated with a cycle of one MS (in the Orbitrap) acquired at a resolution 
of 60,000 at m/z 400, with the top 10 most abundant multiply-charged (2+ and higher) ions in 
a given chromatographic window subjected to MS/MS fragmentation in the linear ion trap. 
An FTMS target values of 1e6 and an ion trap MSn target value of 1e4 was used and with the 
lock mass (445.120025) enabled. Maximum FTMS scan accumulation time of 250 ms and 
maximum ion trap MSn scan accumulation time of 100 ms were used. Dynamic exclusion 
was enabled with a repeat duration of 45 s with an exclusion list of 500 and exclusion 
duration of 30s. 
MS data was analysed using MaxQuant [34] version 1.1.1.36. Data was searched against a 
Human IPI sequence database (v3.68) using following search parameters: trypsin with a 
maximum of 2 missed cleavages, 7 ppm for MS mass tolerance, 0.5 Da for MS/MS mass 
tolerance, with Acetyl (Protein N-term) and Oxidation (M) set as variable modifications and 
carbamidomethyl (C) as a fixed modification. A protein FDR of 0.01 and a peptide FDR of 
0.01 were used for identification level cut offs. Protein quantification based on calculation of 
medium/light, heavy/light and heavy/medium dimethylated peptide ratios was performed 
using razor and unique peptides. The ratio of peptide abundances between Pep6 and PepδV 
affinity purifications was calculated independently for each protein and replicate. For a 
protein to be considered as a true positive in a given replicate its enrichment ratio had to be 
above threshold which was the sum of the median ratio and its absolute deviation (Median + 
MAD) [35]. Proteins with an abundance ratio above the threshold in 2 or 3 replicates were 
considered true components regardless of the number of peptides they have been identified 
with. For proteins found only in one replicate with a ratio above the threshold, to be 
considered a true positive, it had to be identified with at least three peptides. For each tissue 
type, proteins are then classified into 2 groups: High-Confidence group contains proteins 
identified as true positives in all or 2 out of 3 replicas and total group contains all proteins 
identified. 
Analysis of MASC genes causing genetic nervous system diseases 
Gene and phenotype entries were automatically extracted from OMIM [26] using the 
mim2gene file linking via their Entrez Gene identifiers. Diseases caused by MASC proteins 
were further classified, using information in the OMIM entry (Additional file 5), into central 
nervous system (CNS), peripheral nervous system (PNS), both CNS and PNS, or other. All 
diseases affecting the CNS, regardless of presence or absence of PNS involvement, were then 
grouped into chapters of the International Classification of Disease (ICD-10) developed by 
the World Health Organization (WHO). Those OMIM diseases that could not readily be 
found in ICD-10 were assigned to one of the ICD-10 chapters based on their symptoms, if 
possible, or classified as No-ICD 10 correspondence. Diseases in chapter VI (Diseases of the 
Nervous System) were divided into more specific blocks within that chapter. 
To analyse the relevance of postsynaptic genes in syndromic or non-syndromic intellectual 
disability (ID or NSID) a list of genes known to cause these disorders was generated 
(Additional file 6). To create this database all genes linked to the terms “Mental Retardation” 
or “Intellectual Disability” were extracted from GeneCards [36] and added to a list of genes 
causing NSID curated from the scientific literature. Binomial statistics were used to calculate 
enrichment of postsynaptic components in ID or NSID. 
Text-mining and expert curation of MASC gene mutation associations to 
human nervous system disorders 
PubMed abstracts up to August 2014 were searched for Human MASC gene mutations 
associated to disease, using a natural language processing approach to information extraction 
provided in the Linguamatics I2E platform [37]. Disease and disorder ontology terms from 
the Medical Dictionary for Regulatory Activities dictionary (MedDRA, www.meddra.org) 
were combined with a flexible pattern capturing genetic mutation terms, such as mutation, 
polymorphism, deletion, variation, and amino acid substitution patterns such as ‘K483E’, 
requiring mutation terms to be local to the gene, but allowing the disease term to appear 
anywhere in the sentence. The resulting sentences were examined by a biologist, checking 
each for correct gene identity (disambiguation), relevance to human genetics and limiting to 
disorders of nervous system origin, using a simple accept/reject criterion. In the cases where 
many sentence ‘hits’ were obtained to a particular gene and disease term combination, a 
maximum of 10 documents were examined. Redundant disease terms, such as symptomatic 
terms that describe a part of a larger clinical syndrome or disease were manually removed, 
thus we report a single representative PubMed identifier for each gene mutation-disease 
association combination. We then combined the curated text-mined PubMed search results 
with the OMIM extraction results, to produce an overview of the relationship between 
reported Human MASC gene mutations and nervous system disorders. 
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